SavedAdd your journal

Journals / Turkish Journal of Clinics and Laboratory / 2025 / Cilt: 16 Sayı: 4

Prognostic Value of Serum Uric Acid in Predicting Major Adverse Cardiac Events

Serum Ürik Asit Düzeylerinin Majör Advers Kardiyak Olayları Öngörmedeki Prognostik Değeri

Gamze Yeter Arslan(KEPEZ DEVLET HASTANESİ)0000-0002-0114-7448
Serdar Söner(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, DİYARBAKIR GAZİ YAŞARGİL SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-2807-6424
Pages
591–597
Publication Date
2026-01-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Routine SUA measurement upon admission may enhance short-term risk stratification and guide clinical decision- making in patients with NSTE-ACS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Aim:Serum uric acid (SUA) has been increasingly recognized as a potential biomarker reflecting inflammation and oxidative stress in cardiovascular diseases.
📊
Key Findings & Data:This study aimed to investigate the prognostic value of SUA levels in predicting 30-day major adverse cardiac events (MACE) in patients hospitalized with non–ST-elevation myocardial infarction (NSTEMI).
💡
Conclusion & Impact:Routine SUA measurement upon admission may enhance short-term risk stratification and guide clinical decision- making in patients with NSTE-ACS.
🔬Design:Araştırma Makalesi
📍Scope:2024 Verileri
⚙️Variables:Ürik asit · NSTEMI · MACE

Abstract

Abstract Aim:Serum uric acid (SUA) has been increasingly recognized as a potential biomarker reflecting inflammation and oxidative stress in cardiovascular diseases. This study aimed to investigate the prognostic value of SUA levels in predicting 30-day major adverse cardiac events (MACE) in patients hospitalized with non–ST-elevation myocardial infarction (NSTEMI). Methods:This retrospective study included 300 consecutive patients diagnosed with NSTEMI who were hospitalized in the Cardiology Department of Gazi Yaşargil Training and Research Hospital between January 2024 and January 2025. Patients with acute or chronic kidney disease, malignancy, or severe systemic inflammatory disorders were excluded. SUA, troponin T, and lipid profile values were obtained on admission. MACE was defined as a composite of cardiovascular death, recurrent myocardial infarction, urgent revascularization, or rehospitalization due to unstable angina within 30 days. Logistic regression analysis was used to determine independent predictors of MACE. Results:MACE occurred in 28.7% of patients (n=86). The median SUA level was significantly higher in patients who developed MACE compared with those who did not (7.5 vs. 6.5 mg/dL, p=0.001). ROC curve analysis demonstrated that SUA predicted 30- day MACE with an AUC of 0.72. In multivariate logistic regression, elevated SUA (OR=1.45, p=0.03), troponin T (OR=1.62, p=0.01), and diabetes mellitus (OR=1.39, p=0.04) were identified as independent predictors. Conclusion:Serum uric acid is an independent and readily available biomarker associated with early adverse cardiac outcomes in NSTEMI. Routine SUA measurement upon admission may enhance short-term risk stratification and guide clinical decision- making in patients with NSTE-ACS.

Özet

Amaç:Serum ürik asit (SÜA) düzeyleri, kardiyovasküler hastalıklarda inflamasyon ve oksidatif stresin bir göstergesi olarak giderek daha fazla önem kazanmaktadır. Bu çalışmada, non-ST elevasyonlu miyokart enfarktüsü (NSTEMI) tanısıyla yatırılan hastalarda serum ürik asit düzeylerinin 30 günlük majör kardiyak olaylar (MACE) üzerindeki prognostik değerinin araştırılması amaçlandı. Yöntem:Bu retrospektif çalışmaya, Ocak 2024–Ocak 2025 tarihleri arasında Gazi Yaşargil Eğitim ve Araştırma Hastanesi Kardiyoloji Kliniği’nde NSTEMI tanısıyla yatan 300 ardışık hasta dahil edildi. Akut veya kronik böbrek hastalığı, malignite veya ciddi sistemik inflamatuvar hastalığı olanlar dışlandı. Başvuru anında SÜA, troponin T ve lipid profili değerleri kaydedildi. MACE; kardiyovasküler ölüm, tekrarlayan miyokart enfarktüsü, acil revaskülarizasyon veya 30 gün içinde kararsız anjina nedeniyle yeniden hastaneye yatış olarak tanımlandı. Bağımsız belirleyiciler çok değişkenli lojistik regresyon analizi ile değerlendirildi. Bulgular:Hastaların %28,7’sinde (n=86) MACE gelişti. MACE gelişen hastalarda medyan SÜA düzeyi anlamlı olarak daha yüksek bulundu (7,5’a karşı 6,5 mg/dL, p=0.001). ROC eğrisi analizine göre SÜA, 30 günlük MACE’yi öngörmede AUC değeri 0,72 idi. Çok değişkenli analizde yüksek SÜA (OR=1,45, p=0,03), troponin T (OR=1,62, p=0,01) ve diyabetes mellitus (OR=1,39, p=0,04) bağımsız öngörücüler olarak belirlendi. Sonuç:Serum ürik asit düzeyi, NSTEMI hastalarında erken dönem majör kardiyak olaylarla bağımsız olarak ilişkili, kolay erişilebilir bir biyobelirteçtir. Başvuru anında yapılan rutin SÜA ölçümü, kısa dönem risk sınıflamasını güçlendirebilir ve klinik karar sürecine katkı sağlayabilir.

🔖

Cite This Article

Arslan, G. Y., Söner, S. (2026). Prognostic Value of Serum Uric Acid in Predicting Major Adverse Cardiac Events. Turkish Journal of Clinics and Laboratory, Cilt: 16 Sayı: 4, 591–597. https://doi.org/10.18663/tjcl.1799420

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Circulation 2014; 130: e344–e426.
  2. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016; 37: 267–315.
  3. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G et al. The TIMI risk score for unstable angina/non–ST elevation MI. JAMA 2000; 284: 835–42.
  4. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811–21.
  5. Ndrepepa G, Braun S, King L, Fusaro M, Tada T, Cassese S et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol 2012; 109: 1260–5.
  6. Sautin YY, Johnson RJ. Uric acid: the oxidant–antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008; 27: 608–19.
  7. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid–induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–62.
  8. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress through the vascular renin-angiotensin system. Hypertension 2008; 48: 1031–6.
  9. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. JAMA 2000; 283: 2404–10.
  10. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M et al. Prognostic value of serum uric acid in patients with acute coronary syndromes. Circ J 2005; 69: 1031–6.
  11. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.
  12. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010; 62: 170–80.
  13. Strasak AM, Kelleher C, Brant LJ, Rapp K, Ruttmann E, Concin H et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study in 83,683 Austrian men and women. Int J Cardiol 2007; 117: 183–9.
  14. Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez CA, Rivard CJ et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 2016; 29: 3–8.
  15. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015; 33: 1729–41.
  16. Xu X, Hu J, Song N, Chen R, Zhang T, Ding X. Hyperuricemia as an independent predictor of all-cause and cardiovascular mortality: a systematic review and meta-analysis. BMC Cardiovasc Disord 2020; 20: 390.